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INTRODUCTION
Mitochondrial disease comprises a group of disorders re-
sulting from mitochondrial dysfunction and, in particular, 
from defects in the mitochondrial respiratory chain (MRC) 
and associated abnormal oxidative phosphorylation.1,2 
While mitochondrial dysfunction can occur in any organ, 
higher incidences are recorded in organs with high-energy 
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Purpose: Previous studies have shown that neurologic symptoms are dominant in patients with mitochondrial diseases, and 
most of these patients have seizure-related disorders. The epileptic classification of these patients as Lennox-Gastaut syndrome 
(LGS) is as high as 25%. This study aimed to investigate the clinical manifestations, diagnoses, treatments, and epilepsy in LGS, 
which is associated with mitochondrial disease.
Materials and Methods: A retrospective study was conducted on 372 patients who were diagnosed with mitochondrial disease 
between 2006 and 2016. Of these 372 patients, 40 patients diagnosed with LGS were selected, and they were classified into two 
groups based on the history of West syndrome. Patient characteristics were reviewed, and associations between clinical factors 
and outcomes after the treatment were analyzed.
Results: The proportion of individuals with mitochondrial disease with LGS with a history of West syndrome was 32.5%. Among 
the patients with mitochondrial disease with LGS, neonatal seizure (p=0.029), seizure as the first symptom (p=0.018), and gener-
alized paroxysmal fast activity frequency on electroencephalogram (p=0.018) in the group with a history of West syndrome were 
statistically significantly high. The first symptom onset (0.6±0.4 yrs vs. 1.6±0.9 yrs, p=0.003) and first seizure onset (0.9±0.7 yrs vs. 
3.9±3.1 yrs, p<0.001) were significantly faster in patients with a history of West syndrome. 
Conclusion: Close monitoring of the medical condition and early intervention might improve the prognosis of individuals with 
mitochondrial disease with LGS and a history of West syndrome.
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requirements, such as the brain, heart, liver, and skeletal mus-
cle system.2,3
Among the symptoms of mitochondrial disease, neurologic 
symptoms are predominate, and seizures account for the 
greatest proportion thereof.4 Previous studies have shown that 
Lennox-Gastaut syndrome (LGS) accounts for a high propor-
tion of epilepsies in mitochondrial diseases, and its prognosis 
is poor.5,6 LGS is a severe childhood-onset epileptic encepha-
lopathy, characterized by multiple seizure types and progres-
sive mental retardation.5-7 The prognosis of patients with LGS 
follows a catastrophic course from drug resistance to epileptic 
encephalopathy.6
While several studies on mitochondrial disease and LGS 
have been conducted before, studies on LGS with mitochon-
drial disease in children are scarce. Therefore, this study 
aimed to analyze the clinical features, diagnosis, and treat-
ment of children with mitochondrial disease with LGS.
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MaTeRIaLS aND MeThODS
Patients and study design
The medical records of pediatric patients who were diagnosed 
with mitochondrial disease were reviewed; the patients were 
followed up regularly at the Department of Pediatrics of 
Gangnam Severance Hospital between January 2006 and Jan-
uary 2016. The study population consisted of 40 patients 
(16.1%) diagnosed with LGS, among the 248 patients (67%) 
diagnosed with epilepsy and 372 patients who were diag-
nosed with mitochondrial disease based on the diagnostic 
criteria of Bernier, et al.8 The study protocol was approved by 
the Institutional Review Board of the Yonsei University Gang-
nam Severance Hospital (4-2011-0463), and written informed 
consent was obtained from the parents or legal guardians of 
all patients.
Data collection of the clinical characteristics and 
diagnostic evaluation for mitochondrial disease
Diagnostic evaluations for mitochondrial disease were per-
formed by laboratory studies, histology studies, and enzymat-
ic and imaging studies. The degree of serum lactic acidosis 
was defined as mild, moderate, or severe if the increase over 
the normal reference values was at least two-, three-, or four-
fold, respectively. Data on brain magnetic resonance imaging 
(MRI) and magnetic resonance spectroscopy study were also 
collected. Muscle biopsies were performed surgically from the 
quadriceps muscle, and routine histologic, immunohisto-
chemical, and electron microscopic examinations were con-
ducted. Biochemical assays to evaluate MRC enzyme activity 
were also performed, defining the enzyme to be defective 
when residual enzyme activity was <10% of the reference val-
ue.9 Mitochondrial DNA mutation was confirmed in two pa-
tients who suffered mitochondrial encephalomyopathy, lactic 
acidosis, and stroke-like episodes (MELAS) and Leigh syn-
drome, respectively.
Data collection regarding diagnosis and treatment 
options for Lennox-Gastaut syndrome
The diagnostic criteria for LGS included multiple seizure 
types, a specific inter-ictal electroencephalogram (EEG) pat-
tern of diffuse slow background combined with generalized 
slow spike wave (GSSW) in an awake state and generalized 
paroxysmal fast activity (GPFA) during sleep, and progressive 
cognitive impairment. Seizure outcomes were assessed seri-
ally according to seizure type (tonic, tonic-clonic, myoclonic, 
atonic, atypical absence, epileptic spasms, and focal seizures) 
up to and including the most recent visit.10 The treatment was 
divided into antiepileptic drug (AED), ketogenic diet, and sur-
gery. Ketogenic diet was assessed based on the frequency of 
seizures 6 months after the start of the diet.
Patients with LGS were divided into two groups based on a 
history of West syndrome. The two groups were compared in 
terms of clinical variables. In this study, the proportion of mi-
tochondrial disease with LGS with history of West syndrome 
was 32.5%.
Statistical analysis
All analyses were conducted using the Statistical Package for 
the Social Sciences (SPSS) version 22.0 (IBM Corp., Armonk, 
NY, USA). Descriptive statistics were used including the mean, 
standard deviation (SD), median, and range. Parametric t-
tests and chi-square tests were applied to evaluate differences 
between groups. p values <0.05 were considered statistically 
significant.
ReSULTS
General characteristics and clinical status of 
mitochondrial disease at the last visit 
A total of 40 pediatric patients were diagnosed with LGS with 
mitochondrial disease (Table 1). Among the patients, 17 pa-
tients (42.5%) were male, and 23 patients (57.5%) were female. 
In most cases, there was no history of birth abnormality. In re-
gards to birth history, small for gestational age was most fre-
quently recorded.
The initial symptoms of the patients varied, and the most 
common first symptom was seizure (50%), followed by de-
layed development (40%), ataxia, hemiparesis, perinatal as-
phyxia, and loss of consciousness. The mean age of the occur-
rence of the first symptom was 1.5 years (1.5±0.9), and the 
mean age of the first seizure onset as an initial symptom was 3 
years (3.0±3.3). The mean age of diagnosis of LGS was 5 years. 
Mitochondrial disease with LGS with a history of West syn-
drome comprised 32.5%. The duration of transition to LGS af-
ter diagnosis from West syndrome was 1.6 years (1.6±1.8). 
Each patient was regularly followed up at the institute. The 
mean duration of follow-up from the onset of the first symp-
tom was 11 years; from the first seizure, 9.4 years; and from 
LGS diagnosis, 7.8 years.
All patients had involvement of the central nervous system, 
followed by the gastrointestinal and respiratory systems, and 
various organs were affected. Functional state was classified 
as mild for self-ambulation, moderate for wheelchair bound-
ing, and severe for bedridden state and progressed from 60% 
to severe. At the last visit, respiratory assistance was required 
for 15% of the patients, and 37.5% of the patients were receiv-
ing enteral tube feeding.
Diagnostic evaluations of mitochondrial disease 
Serum lactic acid levels were increased in 13 patients (Table 
2). Serum levels of lactic acid were found to be mildly in-
creased, moderately increased, and severely increased in 22.5, 
5, and 5% of patients, respectively. In terms of syndromic di-
agnosis, nonspecific mitochondrial disease, Leigh syndrome, 
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and MELAS were diagnosed in 85, 7.5, and 2.5% of patients, 
respectively. Complex 1 of the MRC complex showed most of 
the defects. MRI showed abnormal findings in 82.5% of pa-
tients, with diffuse atrophy accounting for 70%.
Diagnosis of and treatment options for LGS 
A number of seizure types was observed in 40 patients 
throughout their clinical course, and one patient exhibited 
multiple seizure types (Table 3). These consisted of the follow-
ing: tonic seizures (35%), focal seizures (32.5%), tonic clonic 
seizures (32.5%), myoclonic seizures (30%), atonic seizure 
(30%), absence seizure (17.5%), clonic seizures (5%), and oth-
ers (27.5%).
The EEGs of all patients showed generalized slow and dis-
organized back ground rhythm. Additionally, 20% of the pa-
Table 1. General Characteristics of 40 Patients and Clinical Status of 
Mitochondrial Disease at the Last Visit 
Characteristics Prevalence (n=40)
Sex 17(42.5):23(57.5)
Birth history
Prematurity (<37 wks) 1 (2.5)
Small for gestational age (<10%) 6 (15)
Prenatal asphyxia 3 (7.5)
Hypoxic ischemic encephalopathy 2 (5.0)
Neonatal seizure 3 (7.5)
Family history
None 35 (87.5)
Epilepsy 3 (7.5)
Mitochondrial disease 1 (2.5)
Neurologic disorder 1 (2.5)
First presenting symptoms
Seizure 20 (50)
Delayed development 16 (40)
Ataxia 1 (2.5)
Hemiparesis 1 (2.5)
Perinatal asphyxia 1 (2.5)
Loss of consciousness 1 (2.5)
Age of first symptoms (yr) 1.5±0.9
Age of first seizure (yr) 3.0±3.3
History of West syndrome 13 (32.5)
Age of LGS diagnosis (yr) 5.0±3.7
From West syndrome diagnosis to LGS (yr) 1.6±1.8
Follow-up duration (yr)
From first symptom to last visit 11.0±5.4
From first seizure to last visit 9.4±4.5
From LGS diagnosis to last visit 7.8±4.2
Organ involvement
Neuromuscular system 40 (100)
Gastrointestinal system 10 (25)
Respiratory system 4 (10.0)
Cardiologic system 2 (5.0)
Eye 2 (5.0)
Renal system 1 (2.5)
Endocrinologic system 1 (2.5)
Hematologic system 1 (2.5)
Psy 1 (2.5)
Clinical severity at last visit
Functional state
Mild 5 (12.5)
Moderate 10 (25)
Severe 20 (50)
Expired 5 (12.5)
Respiration
Tracheostomy 4 (10.0)
Oxygen dependency 1 (2.5)
Home ventilator 1 (2.5)
Enteral tube feeding 12 (37.5)
LGS, Lennox-Gastaut syndrome.
Data are given as mean±standard deviation or as number (percentage).
Table 2. Diagnostic Evaluations of Mitochondrial Disease and MRI Find-
ings at the Last Visit
Evaluation Findings
Prevalence 
(n=40)
Serum lactate level
Normal 23 (57.5)
Mildly increased (1–2-fold) 9 (22.5)
Moderately increased (2–3-fold) 2 (5.0)
Severely increased (≥3-fold) 2 (5.0)
Syndromic diagnosis
Nonspecific mitochondrial disease 34 (85)
Leigh syndrome 5 (7.5)
MELAS 1 (2.5)
Biochemical enzyme assay
Normal 2 (5.0)
MRC complex I defect 36 (90)
MRC complex IV defect 2 (5.0)
Muscle pathology 
Light microscopy
Normal 4 (10.0)
Mitochondrial specific finding 28 (70)
Mitochondrial nonspecific finding 8 (20)
Electron microscopy
Normal 23 (57.5)
Pleoconia 14 (35)
Megaconia 11 (27.5)
MRI at last visit
Normal 7 (17.5)
Basal ganglia signal abnormality 6 (15.0)
Thalamus signal abnormality 3 (7.5)
Brainstem signal abnormality
Midbrain 1 (2.5)
Pons 2 (5.0)
Medulla 2 (5.0)
Cortex signal abnormality 11 (27.5)
Cerebellar atrophy 11 (27.5)
White matter signal abnormality 17 (42.5)
Diffuse atrophy 28 (70.0)
MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like 
episodes; MRC, mitochondrial respiratory chain; MRI, magnetic resonance 
imaging.
Data are given as number (percentage).
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tients showed focal slowing. For epileptiform discharges, GSSW 
was seen in 57.5%, GPFA in 50%, and multifocal in 67.5%.
The mean seizure frequency at the time of the diagnosis was 
172.1±298.4 per month. One year after diagnosis, the mean 
seizure frequency was 144.8±473.4 per month, and in the last 
visit after diagnosis, the mean seizure frequency was 63.8± 
134.6 per month. Seizure outcomes for the 40 patients were as 
follows: seizure frequency decreased >50% at 1 year after di-
agnosis in 16 patients (40%), and seizure frequency decreased 
>50% at the time of the last visit in 18 patients (45%). The pa-
tients used 2.7±1.3 AEDs at the time of diagnosis, 3.4±1.3 AEDs 
at 1 year after diagnosis, and 3.7±1.7 AEDs at the last visit after 
diagnosis. Four patients underwent surgery, and all under-
went corpus callosotomy.
Subgroup analysis in LGS with or without a history 
of West syndrome 
To investigate the impact of a history of West syndrome, the 
study population was divided into groups (Table 4). Among 
the patients with mitochondrial disease with LGS, neonatal 
seizure (p=0.029) and seizure as the first symptom (p=0.018) 
in the group with a history of West syndrome were significant-
ly higher. The first symptom onset (0.6±0.4 yrs vs. 1.6±0.9 yrs, 
p=0.003) and first seizure onset (0.9±0.7 yrs vs. 3.9±3.1 yrs, 
p<0.001) were significantly faster in the group with a history of 
West syndrome. Organ involvement and clinical severity were 
not statistically significant.
Among the patients with mitochondrial disease with LGS, 
the incidence of abnormal findings on electron microscopy 
was significantly higher in the group with no history of West 
syndrome (Table 5). MRI findings were not statistically signifi-
cant at the last visit.
In the West syndrome history group, other seizure type was 
more frequent than in the no history of West syndrome group 
(Table 6). This may be the result of spasm being classified as 
other type. GPFA frequency on EEG (p=0.018) in the group with 
a history of West syndrome was significantly higher. The num-
ber of AEDs seemed to increase at the last visit in the group 
with a history of West syndrome, although this was not statisti-
cally significant. No significant difference was observed in sei-
zure reduction rate and treatment between the two groups.
DISCUSSION
Neurologic symptoms are predominant in patients with mito-
chondrial disease, and the most common clinical presenta-
tion of mitochondrial diseases is epileptic seizure.11 LGS ac-
counts for a small proportion of the epilepsies. The prevalence 
of LGS is estimated between 1% and 2% of all patients with 
epilepsy and between 1% and 10% of childhood epilepsies.12,13 
However, the exact prevalence of mitochondrial epilepsy is 
not known, although seizures have been reported to occur in 
35% to 60% of individuals with biochemically confirmed mi-
tochondrial disease.14,15 Studies systematically examining epi-
lepsy phenotypes in the context of mitochondrial disease are 
lacking.4,14,16 In one series of 48 individuals with epilepsy and 
confirmed MRC defects, two had Ohtahara syndrome, 10 had 
West syndrome, 12 had LGS, two had Landau-Kleffner syn-
drome, 14 had generalized epilepsy, and eight had focal epi-
lepsy.4 In the current study, 67% of the patients with mitochon-
Table 3. Diagnosis and Treatment Options for Lennox-Gastaut Syndrome 
Clinical feature Specification
Prevalence 
(n=40)
Seizure type
Tonic 14 (35)
Focal 13 (32.5)
Tonic-clonic 13 (32.5)
Myoclonic 12 (30)
Atonic 12 (30)
Absence 7 (17.5)
Clonic 2 (5.0)
Other 11 (27.5)
Electroencephalography
Background rhythm
Slow and disorganized background 40 (100)
Focal slowing 8 (20)
Epileptiform discharges
GSSW 23 (57.5)
GPFAs 20 (50)
Multifocal sharp/spike waves 27 (67.5)
Focal sharp/spike waves 6 (15)
Seizure frequency
(per month)
At the time of diagnosis 172.1±298.4
1 year after diagnosis 144.8±473.4
Last visit after diagnosis 63.8±134.6
Reduction rate (1 yr after diagnosis)
Seizure-free 7 (17.5)
Reduction ≥50% 16 (40)
Reduction <50% 2 (5.0)
Aggravation 15 (37.5)
Reduction rate (last visit)
Seizure-free 11 (27.5)
Reduction ≥50% 18 (45)
Reduction <50% 2 (5.0)
Aggravation 7 (17.5)
Antiepileptic drugs
At the time of diagnosis 2.7±1.3
1 year after diagnosis 3.4±1.3
Last visit after diagnosis 3.7±1.7
Ketogenic diet
Yes 24 (60) 
Retention rate
Retention ≥6 mon 14/24 (58.3)
Retention <6 mon 10/24 (41.7)
Epilepsy surgery Yes 4 (10)
GSSW, generalized slow spike wave; GPFA, generalized paroxysmal fast ac-
tivity.
Data are given as mean±standard deviation or number (percentage).
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Table 4. Analysis of General Characteristics by Subgroup and Clinical Status of Mitochondrial Disease at the Last Visit
Characteristics History of West syndrome (n=13) No history of West syndrome (n=27) p value
Sex (male:female) 6 (46.2):7 (53.8) 11 (40.7):16 (59.3) 0.746
Birth history
Prematurity (<37 wks) 0 (0) 1 (3.7) 0.675
SGA 1 (7.7) 5 (18.5) 0.351
Prenatal asphyxia 0 (0) 3 (11.1) 0.296
HIE 1 (7.7) 1 (3.7) 0.550
Neonatal seizure 3 (23.1) 0 (0) 0.029
Family history
None 12 (92.3) 23 (85.2) 0.469
Epilepsy 1 (7.7) 2 (7.4) 0.704
Mitochondrial disease 0 (0) 1 (3.7) 0.675
Neurologic disorder 0 (0) 1 (3.7) 0.675
First presenting symptoms
Seizure 10 (76.9) 10 (37) 0.018
Delayed development 3 (23.1) 13 (48.1) 0.130
Ataxia 0 (0) 1 (3.7) 0.675
Hemiparesis 0 (0) 1 (3.7) 0.675
Perinatal asphyxia 0 (0) 1 (3.7) 0.675
LOC 0 (0) 1 (3.7) 0.675
Age of first symptoms (yr) 0.6±0.4 1.6±0.9 0.003
Age of first seizure (yr) 0.9±0.7 3.9±3.1 <0.001
Follow-up duration (yr)
From first symptom to last visit 9.5±3.7 11.7±5.9 0.224
From first seizure to last visit 9.2±3.9 9.6±4.8 0.786
From LGS diagnosis to last visit 7.5±3.4 2.9±4.6 0.806
Organ involvement
Neuromuscular system 13 (100) 27 (100) -
Gastrointestinal system 5 (38.5) 5 (18.5) 0.165
Respiratory system 2 (15.4) 2 (7.4) 0.392
Cardiologic system 1 (7.7) 1 (3.7) 0.550
Eye 2 (15.4) 0 (0) 0.100
Renal system 1 (7.7) 0 (0) 0.325
Endocrinologic system 1 (7.7) 0 (0) 0.325
Hematologic system 1 (7.7) 0 (0) 0.325
Psy 0 (0) 1 (3.7) 0.325
Clinical severity
Functional state
Mild 0 (0) 5 (18.5) 0.123
Moderate 3 (23.1) 7 (25.9) 0.586
Severe 8 (61.5) 12 (44.4) 0.311
Expire 2 (15.4) 3 (11.1) 0.531
Respiration
Oxygen dependency 0 (0) 1 (3.7) 0.675
Tracheostomy 1 (7.7) 3 (11.1) 0.608
Home ventilator 0 (0) 1 (3.7) 0.675
Enteral feeding
Yes 7 (53.8) 8 (29.6) 0.129
No 6 (46.2) 19 (70.4) 0.129
SGA, small for gestational age (<2500 gm); HIE, hypoxic ischemic encephalopathy; LOC, loss of consciousness; LGS, Lennox-Gastaut syndrome.
Data are given as mean±standard deviation or number (percentage).
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drial disease were diagnosed with epilepsy, and 16% of them 
were diagnosed with LGS. When comparing the current study 
with previous studies, LGS was found more frequently in pa-
tients with mitochondrial disease than expected. 
The etiology of LGS has been divided into two groups. Ap-
proximately 75% of cases are thought to be symptomatic, im-
plying an identifiable cause, such as a cerebral malformation 
or hypoxic ischemic injury.17-19 Identifiable causes are usually 
the result of a static brain disorder; progressive metabolic dis-
orders are extremely rare. The cryptogenic group (no appar-
ent cause and no neurologic precedents) may account for ap-
proximately 25% of cases.18 When LGS has no apparent cause, 
a genetic predisposition20 or autoimmune influence has been 
hypothesized.21 In this study, patients were diagnosed with 
mitochondrial disease as underlying disease, and etiology 
was structural or metabolic disease. The LGS etiology known 
so far includes encephalitis and meningitis, tuberous sclero-
sis, brain malformations, hypoxia ischemia injury, frontal lobe 
lesion, traumatic brain injury, and the like.22 There is a history 
of infantile spasms in 9–39% of patients with LGS. A clinic-
based study designed to investigate the etiology of LGS found 
that 24 of 72 LGS cases (33%) evolved from West syndrome.23 
A Cochrane review suggested that about 20% of LGS cases are 
preceded by West syndrome.18 Weinmann24 also noted that 
17.8% of 174 children with LGS had preceding West syn-
drome. In this study, 13 of 40 (32.5%) patients with LGS had a 
history of West syndrome, and the rate of transition from West 
syndrome to LGS was not significantly different from previous 
studies. Moreover, when migrating from West syndrome to 
LGS, no significant difference was observed in the rate of mi-
gration of mitochondria disease.
No difference was observed in general characteristics and 
Table 5. Analysis of Diagnosis Evaluations and MRI of Mitochondrial Disease 
Evaluation Findings History of West syndrome (n=13) No History of West syndrome (n=27) p value
Serum lactic acidosis
Normal 8 (61.5) 15 (65.2) 0.552
Mildly increased (1–2-fold) 3 (23.1) 6 (26.1) 0.586
Moderately increased (2–3-fold) 0 (0) 2 (8.7) 0.402
Severely increased (≥3-fold) 2 (15.4) 0 (0) 0.124
Syndromic diagnosis
Nonspecific mitochondrial disease 12 (92.3) 22 (81.5) 0.351
Leigh syndrome 1 (7.7) 4 (14.8) 0.469
MELAS 0 (0) 1 (3.7) 0.675
Biochemical enzyme assay
Normal 1 (7.7) 1 (3.7) 0.550
MRC complex I defect 11 (84.6) 25 (92.6) 0.392
MRC complex IV defect 1 (7.7) 1 (3.7) 0.550
Muscle pathology 
Light microscopic
Normal 10 (76.9) 18 (66.7) 0.391
Mitochondrial specific finding 1 (7.7) 7 (25.9) 0.179
Mitochondrial nonspecific finding 2 (15.4) 2 (7.4) 0.392
Electron microscopic changes
Normal 11 (84.6) 12 (44.4) 0.016
Pleoconia 2 (15.4) 9 (33.3) 0.211
Megaconia 2 (15.4) 12 (44.4) 0.071
MRI at last visit
Normal 1 (7.7) 6 (22.2) 0.254
Basal ganglia signal abnormality 1 (7.7) 5 (18.5) 0.351
Thalamus signal abnormality 1 (7.7) 2 (7.4) 0.704
Brainstem signal abnormality
Midbrain 0 (0) 1 (3.7) 0.675
Pons 1 (7.7) 1 (3.7) 0.550
Medulla 1 (7.7) 1 (3.7) 0.550
Cortex signal abnormality 4 (30.8) 7 (25.9) 0.514
Cerebellar atrophy 3 (23.1) 8 (29.6) 0.486
White matter signal abnormality 7 (53.8) 10 (37.0) 0.314
Diffuse atrophy
Mild 8 (61.5) 14 (51.9) 0.585
Severe 3 (23.1) 1 (3.7) 0.092
MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MRC, mitochondrial respiratory chain; MRI, magnetic resonance imaging.
Data are given as number (percentage).
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mitochondrial variables when patients with LGS were divided 
into two groups based on the history of West syndrome. Clini-
cal aspects, such as organ involvement and clinical severity, 
were not different. From the diagnostic point of view, no dif-
ference was observed in the syndromic diagnosis, biochemi-
cal enzyme assay, and MRI between the two groups. However, 
in the clinical aspect, first symptom onset was significantly 
faster in the group with a history of West syndrome, and sei-
zure as the first symptom in the group with a history of West 
syndrome was high with statistical significance. Previous 
studies showed that the most common first symptom was sei-
zure (n=35, 50%), followed by delayed development (n=25, 
36%), and the mean age at the first symptom was 1.8 years 
(range: 0–9.9 years, SD: 2.5 years) in mitochondrial disease.25 
As reported in another study, the first manifestations of the 
disease were recorded at a median age of 7 months (range: 
0–16 years) and encompassed a wide range of symptoms, in-
cluding nonspecific psychomotor delay (38%), metabolic aci-
dosis (14%), failure to thrive (10%), acute or subacute regres-
sion (9%), visceral involvement (liver dysfunction, 4%; 
Table 6. Analysis of Diagnosis and Treatment Options of Lennox-Gastaut Syndrome
Clinical Features Specification History of West syndrome (n=13) No History of West syndrome (n=27) p value
Seizure type
Tonic 7 (53.8) 7 (25.9) 0.085
Focal 3 (23.1) 10 (37.0) 0.305
Tonic-clonic 3 (23.1) 10 (37.0) 0.305
Myoclonic 3 (23.1) 9 (33.3) 0.391
Atonic 3 (23.1) 9 (33.3) 0.391
Absence 1 (7.7) 6 (22.2) 0.254
Clonic 0 (0) 2 (7.4) 0.450
Other 8 (61.5) 3 (11.1) 0.002
Electroencephalography
Background rhythm
Slow and disorganized background 13 (100) 27 (100) -
Focal slowing 3 (23.1) 5 (18.5) 0.521
Epileptiform discharges
GPFAs 10 (76.9) 10 (37.0) 0.018
GSSW 7 (53.8) 16 (59.3) 0.504
Focal sharp/spike waves 0 (0) 6 (22.2) 0.077
Multifocal sharp/spike waves 11 (84.6) 16 (53.9) 0.105
Seizure frequency 
At the time of diagnosis 283.2±469.4 118.6±150.8 0.103
1 year after diagnosis 321.9±808.7 59.7±105.5 0.266
Last visit after diagnosis 125.0±179.2 32.0±93.7 0.042
Reduction rate (1 yr after diagnosis)
Seizure-free 0 (0) 7 (25.9) 0.074
Reduction ≥50% 7 (53.8) 9 (33.3) 0.185
Reduction <50% 1 (7.7) 1 (3.7) 0.550
Aggravation 5 (38.5) 10 (37.0) 0.599
Reduction rate (last visit)
Seizure free 1 (7.7) 10 (37.0) 0.060
Reduction ≥50% 8 (61.5) 10 (37.0) 0.207
Reduction <50% 1 (7.7) 1 (3.7) 0.573
Aggravation 3 (23.1) 4 (14.8) 0.058
Antiepileptic drugs
At the time of diagnosis 2.7±1.3 2.7±1.4 0.979
1 year after diagnosis 3.9±1.1 3.2±1.3 0.093
Last visit after diagnosis 4.3±1.0 3.4±1.8 0.058
Ketogenic diet
Yes 9 (69.2) 15 (55.6) 0.503
Retention rate
Retention ≥6 mon 7/9 (77.8) 7/15 (46.7) 0.082
Retention <6 mon 2/9 (22.2) 8/15 (53.3) 0.082
Epilepsy surgery Yes 0 (0) 4 (14.8) 0.192
GPFA, generalized paroxysmal fast activity; GSSW, generalized slow spike wave.
Data are given as mean±standard deviation or number (percentage).
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hypertrophic cardiomyopathy, 3%), and various combina-
tions of focal neurologic symptoms (22%), including seizures, 
ataxia, extrapyramidal signs, muscle weakness or pain, ptosis, 
and headache.15 The age at presentation of the first symptoms 
was a major prognostic factor for mortality. Infants presenting 
their first symptoms before 6 months of age have a 10-fold 
higher risk of mortality during the observation period than 
those presenting later. According to Arce-Portillo, statistically 
significant poor prognostic factors were linked to age at onset 
of spasms (<4 months), the presence of epileptic seizures, and 
delayed psychomotor development before the onset of 
spasms.26 In the group with a history of West syndrome, the 
age at which the first seizure occurred was markedly earlier, 
with statistical significance. In a previous study, early age at 
first seizure in patients with LGS was consistent with observa-
tions by Berg, et al.27 who reported an increased risk of intrac-
table seizures among children with early age at first seizure.
Several studies have shown that the younger the age, the 
worse the prognosis. When mitochondrial disease is diag-
nosed at an early age, it can be converted to intractable epi-
lepsy, and close monitoring is required. On the diagnostic side, 
cases with normal muscle biopsy were significantly higher in 
the group with a history of West syndrome. The reason for the 
high rate of normal muscle biopsy results in cases with a his-
tory of West syndrome is believed to be due to examinations 
done at a younger age. The normal ranges of muscle biopsy 
according to age group are not clearly established yet. There-
fore, it is not easy to correct by age even if the result were ab-
normal. As West syndromes present at relatively earlier age, 
muscle biopsies tend to be performed at an earlier age. There 
could be a possibility of this affecting our results.
Some differences were observed in the epilepsy-related 
variables according to the presence or absence of the history 
of West syndrome. In the current study, history of neonatal 
seizure was significantly higher in patients with a history of 
West syndrome. In a study by von Kleist-Retzow, et al.,28 pre-
natal manifestations of MRC deficiencies were noted includ-
ing intrauterine growth restriction (IUGR), multiple congeni-
tal malformations, and prematurity (in 68 of 300 patients). In 
a study by Gibson, et al.,29 prematurity (gestational age of 37 
weeks) was noted in 12.6% of the 107 patients. Of the 85 in-
fants with known birth weights, 24 were in the 10th percentile 
for gestational age, and nine of those were in the <3rd percen-
tile. Patients usually presented with >one symptom or sign in 
the neonatal period. Most patients presented with an enceph-
alomyopathic form, which included any of encephalopathy, 
seizures, hypotonia, ophthalmologic manifestations, or a 
combination thereof. In other studies, IUGR was the highest 
in the birth histories of mitochondrial diseases. Besides neo-
natal timing, although several variables may be important, 
neonatal seizure may be an important factor in the cases of 
patients with LGS with a history of West syndrome.
GPFA and frequency on EEG in the group with a history of 
West syndrome were significantly high. GPFA is a rather 
unique generalized rhythmic EEG finding of unknown signifi-
cance, with a frequency of 8–26 Hz (mostly 10–14 Hz), lasting 
for 2–50 seconds.30 This interesting pattern is usually noted 
during sleep in symptomatic and cryptogenic generalized ep-
ilepsies, and it is one of the EEG constituents of LGS.17,31 Thus, 
GPFA usually indicates poor prognosis, drug-refractory epi-
lepsy with tonic-axial seizures, and mental retardation.32 A 
previous study suggested that a breakdown in gamma-ami-
nobutyric acid-ergic inhibition due to a malignant evolution 
in certain secondarily generalized epilepsies results in a trans-
formation of the GSSW pattern to GPFA with tonic seizure 
manifestations; hence, GSSW is a more stable (standard) EEG 
pattern in many syndromes.33 In a long-term follow-up study, 
Yagi34 described the evolution of EEG in patients with LGS. 
Initially, GSSW discharges disappear, while GPFA and multi-
focal spikes remain. This is followed by the disappearance of 
GPFA and finally the decrease and disappearance of multifo-
cal spikes. There is not much information about the meaning 
of GPFA. In previous studies, the rate of transition from West 
syndrome to LGS has been discussed extensively and is 
known to be performed at a nonsignificant rate. In the current 
study, more GPFA in the group with a history of West syn-
drome was thought to be due to West syndrome being more 
electrophysiologically unstable. The seizure frequency at the 
last visit was statistically significantly higher in the presence of 
the West syndrome history. Considering the electrophysiolog-
ical significance of GPFA, it is assumed that there is more clin-
ical instability when there is more seizure frequency at the last 
visit with the history of West syndrome.
This study has some limitations because of its retrospective 
design. It is limited in that a prospective randomized model 
setting is not proceeded in selecting the subjects and setting 
other research items. This study was conducted in patients 
with mitochondrial disease with rare diseases in a pediatric 
population. Despite these limitations, subgroup analysis was 
carried out by collecting a small number of patients with mi-
tochondrial disease. LGS is an uncommon epileptic encepha-
lopathy, and mitochondrial disease is a rare disease. LGS in 
mitochondrial disease has not been investigated much. In pa-
tients with LGS with mitochondrial disease as a baseline dis-
ease, an overall understanding of the natural course of the 
underlying disease is important, and an individualized ap-
proach and plan based on the patient’s history may be need-
ed. If more data are gathered in the future, it is expected that 
individualized strategies will be developed.
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